Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FEMY vs AVR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–3 Matrix Metrics)

AVR Overall Winner 6-Pillar Tally: FEMY 1 – 4 AVR (1 Tie) Matrix Metrics: FEMY 3 – 4 AVR

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas AVR carries 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. AVR 48.2/100 HOLD), AVR captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -763.9% operating margin) and revenue trajectory (+21.0% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FEMY vs AVR
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92
AVR NASDAQ Head-to-Head Winner
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$5.70
+5.17% 1D
Market Cap $528.4M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.56β · 77% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 58.0 Fund 49.0 Flow 57.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 42
RSI-14: 42.5 · SMA20: $5.93 · SMA50: $6.90

6-Pillar Scorecard Institutional Category Breakdown (FEMY 1 – 4 AVR)

Columns: Metric · FEMY · AVR
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x 133.9x
2. Growth & Scale AVR
Revenue Growth (YoY) -18.9% +21.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $2.3M
Market Cap $11.9M $528.4M
3. Profitability & Quality AVR
Gross Margin 60.9% 75.8%
Operating Margin -763.9% -4880.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -425.0% -93.3%
4. Balance Sheet & Cash Flow AVR
Cash Generation (TTM) -$19M -$94M
Cash Flow Margin N/A N/A
Net Cash / Leverage -$658,045 Net Debt (0.65x D/E) $216M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 58.5% (52nd %ile)
Put/Call OI Skew N/A 0.66x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FEMY (3) vs AVR (4)
Institutional Metric FEMY AVR Criterion Row Edge
Market Capitalization
Scale
$11.9M $528.4M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-18.9% +21.0% Higher Growth AVR
Operating Margin (TTM)
Profitability
-763.9% -4880.4% Higher Margin FEMY
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-425.0% -93.3% Higher ROE AVR
52-Week Range Position
Momentum
17% ($0–$6) 31% ($3–$11) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
4.01β · 72% Vol 1.56β · 77% Vol Lower Realized Risk FEMY
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 48.2 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.9% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · 133.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M (-$658,045 Net Debt (0.65x D/E)) -$94M ($216M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +16.63 pp
FEMY: -22.42% · AVR: -5.79%
3M Horizon AVR +1.32 pp
FEMY: -41.82% · AVR: -40.5%
6M Horizon FEMY +277.51 pp
FEMY: +252.81% · AVR: -24.7%
1Y Horizon FEMY +4.38 pp
FEMY: +54.78% · AVR: +50.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FEMY Revenue AVR Revenue FEMY Op. Margin AVR Op. Margin Margin Leader
FY2020 $0M N/A -668.0% N/A FEMY
FY2021 $0M N/A -706.7% N/A FEMY
FY2022 $0M N/A -961.7% N/A FEMY
FY2023 $0M N/A -1353.4% N/A FEMY
FY2024 $0M $0M -1091.8% -2899.4% FEMY
FY2025 $0M $0M -767.0% -4908.2% FEMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVR BREAKDOWN
101d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 52nd %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $528.4M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FEMY vs AVR Key Questions & Quantitative Answers

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas AVR carries 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. AVR 48.2/100 HOLD), AVR captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -763.9% operating margin) and revenue trajectory (+21.0% vs. -18.9% YoY). Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVR leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with AVR at +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), FEMY cumulative revenue shifted N/A while AVR shifted N/A. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVR.

FEMY screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 133.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus AVR (-93.3% ROE) capital efficiency.

In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, AVR carries 58.5% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.